<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04029012</url>
  </required_header>
  <id_info>
    <org_study_id>Penthrox in Rezūm BPH - Pilot</org_study_id>
    <nct_id>NCT04029012</nct_id>
  </id_info>
  <brief_title>Penthrox in Rezūm BPH - Pilot</brief_title>
  <official_title>A Pilot Study to Assess Efficacy and Safety of Methoxyflurane for Pain Control During Convective Thermal Therapy Using Rezūm System in Benign Prostatic Hyperplasia (BPH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dean Elterman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Can-Am HIFU Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-labeled, single-centre study&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who have elected Convective Thermal Therapy using Rezūm System for the management of&#xD;
      their BPH and fulfilled inclusion and exclusion criteria will sign informed consent form for&#xD;
      the study. Patient will use Methoxyflurane inhaler (Penthrox™) on top of standard oral&#xD;
      analgesia including oral lorazepam, oral Percocet® (oxycodone and acetaminophen) or oxycodone&#xD;
      immediate-release, and intra-urethral lidocaine gel (Xylocaine®). Intravenous propofol will&#xD;
      be used as rescue analgesia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">September 2019</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain intensity</measure>
    <time_frame>immediately after final injection of Rezūm treatment</time_frame>
    <description>Visual Analog Scale (VAS)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Pain</condition>
  <condition>BPH</condition>
  <arm_group>
    <arm_group_label>Penthrox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>methoxyflurane inhaler (Penthrox)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methoxyflurane</intervention_name>
    <description>Methoxyflurane inhaler before Rezum procedure</description>
    <arm_group_label>Penthrox</arm_group_label>
    <other_name>Penthrox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male subjects of ≥ 18 years of age&#xD;
&#xD;
          -  Patient who has elected Convective Thermal Therapy using Rezūm System for the&#xD;
             management of their benign prostatic hyperplasia.&#xD;
&#xD;
          -  No contra-indication on using Methoxyflurane inhaler (Penthrox™).&#xD;
&#xD;
          -  Willing and able to accurately complete the required questionnaires.&#xD;
&#xD;
          -  Willing and able to provide signed and dated informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ongoing use of analgesic agents for chronic pain.&#xD;
&#xD;
          -  Concomitant use of nephrotoxic agents.&#xD;
&#xD;
          -  INR &gt; 4.&#xD;
&#xD;
          -  Use of Methoxyflurane inhaler (Penthrox™) within the previous 3 months.&#xD;
&#xD;
          -  Known allergy to Lorazepam, Percocet/ Oxycodone, or Xylocaine® gel.&#xD;
&#xD;
          -  Known personal or familial hypersensitivity to Methoxyflurane inhaler (Penthrox™) or&#xD;
             other halogenated anesthetics.&#xD;
&#xD;
          -  Clinically significant respiratory depression, cardiovascular instability, renal or&#xD;
             hepatic impairment.&#xD;
&#xD;
          -  An altered level of consciousness, due to any cause, including head injury, drugs, or&#xD;
             alcohol.&#xD;
&#xD;
          -  Known or genetically susceptible to malignant hyperthermia or a history of severe&#xD;
             adverse reactions in either patient or relatives.&#xD;
&#xD;
          -  A history of liver dysfunction after previous Methoxyflurane inhaler (Penthrox™) use&#xD;
             or other halogenated anesthetics.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Patient with BPH</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 19, 2019</study_first_submitted>
  <study_first_submitted_qc>July 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2019</study_first_posted>
  <last_update_submitted>July 22, 2019</last_update_submitted>
  <last_update_submitted_qc>July 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Can-Am HIFU Inc.</investigator_affiliation>
    <investigator_full_name>Dean Elterman</investigator_full_name>
    <investigator_title>Clinician Investigator/ Urologist</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methoxyflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

